WO1998011244A2
(en)
|
1996-09-11 |
1998-03-19 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Aav4 vector and uses thereof
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
JP2002538770A
(ja)
*
|
1998-11-10 |
2002-11-19 |
ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
ウイルスベクターとその製造及び投与の方法
|
AU7739000A
(en)
|
1999-10-01 |
2001-05-10 |
University Of Florida |
Temperature-sensitive regulation of viral vector production
|
US6506600B2
(en)
|
2000-03-22 |
2003-01-14 |
University Of Arkansas |
Secreting products from skin by adeno-associated virus (AAV) gene transfer
|
US6855314B1
(en)
*
|
2000-03-22 |
2005-02-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector for transducing brain cells and lung cells
|
US7056502B2
(en)
|
2000-04-28 |
2006-06-06 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
|
EP1381276A4
(de)
*
|
2001-04-13 |
2005-02-02 |
Univ Pennsylvania |
Verfahren zur behandlung oder zur entwicklungsverlangsamung von blindheit
|
DE10120265A1
(de)
*
|
2001-04-25 |
2002-11-14 |
Deutsches Krebsforsch |
AAV-Helferplasmide zur Helfervirus-freien Verpackung und Pseudotypisierung von AAV-Vektoren
|
US7271150B2
(en)
|
2001-05-14 |
2007-09-18 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified growth hormone
|
US8241622B2
(en)
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
CN105671005B
(zh)
|
2001-11-13 |
2020-09-15 |
宾夕法尼亚大学托管会 |
检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
|
AU2002360291A1
(en)
|
2001-12-17 |
2003-06-30 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 8 sequences
|
EP3339430A1
(de)
|
2001-12-17 |
2018-06-27 |
The Trustees of The University of Pennsylvania |
Adenoassoziierte virus(aav)-serotyp 9-sequenzen, vektoren damit und verwendungen davon
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
US8927269B2
(en)
|
2003-05-19 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Avian adenoassociated virus and uses thereof
|
NZ545656A
(en)
|
2003-09-01 |
2009-02-28 |
Amc Amsterdam |
AAV vectors for in vivo gene therapy of rheumatoid arthritis
|
EP2322638A1
(de)
|
2003-09-01 |
2011-05-18 |
Academisch Medisch Centrum |
AAV Vektoren für die in vivo Gentherapie von rheumatischer Arthritis
|
DK2292779T3
(en)
|
2003-09-30 |
2017-02-27 |
Univ Pennsylvania |
ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
|
WO2005056807A2
(en)
*
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
WO2005058937A2
(en)
|
2003-12-12 |
2005-06-30 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
|
WO2006029196A1
(en)
*
|
2004-09-08 |
2006-03-16 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of H Ealth |
Transcytosis of adeno-associated viruses
|
WO2006066066A2
(en)
|
2004-12-15 |
2006-06-22 |
University Of North Carolina At Chapel Hill |
Chimeric vectors
|
EP4234687A2
(de)
|
2005-04-07 |
2023-08-30 |
The Trustees of the University of Pennsylvania |
Verfahren zur erhöhung der funktion eines aav-vektors
|
WO2006119432A2
(en)
|
2005-04-29 |
2006-11-09 |
The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services |
Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
|
US8921050B2
(en)
|
2006-03-17 |
2014-12-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of diagnosing renal cell carcinoma
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
ES2634118T3
(es)
|
2009-02-11 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Vectores de virus modificados y métodos para fabricar y utilizar los mismos
|
MX2011010097A
(es)
|
2009-03-27 |
2011-10-19 |
Proyecto Biomedicina Cima Sl |
Metodos y composiciones para el tratamiento de cirrosis y fibrosis hepatica.
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
JP2014503173A
(ja)
|
2009-11-05 |
2014-02-13 |
プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ |
制御された発現系
|
ES2683695T3
(es)
|
2010-01-12 |
2018-09-27 |
The University Of North Carolina At Chapel Hill |
Repeticiones terminales invertidas restrictivas para vectores virales
|
EA202091105A1
(ru)
*
|
2010-04-23 |
2020-12-30 |
Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. |
Композиции гуанилатциклазы и способы лечения врожденного амавроза лебера типа 1 (lca1)
|
ES2698203T3
(es)
|
2010-04-23 |
2019-02-01 |
Univ Massachusetts |
Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
US9309534B2
(en)
|
2010-07-12 |
2016-04-12 |
Universidad Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
ES2661680T3
(es)
|
2011-04-21 |
2018-04-03 |
University Of Massachusetts |
Composiciones basadas en VAAr y métodos para tratar deficiencias de alfa-1 anti-tripsina
|
EP3693025B1
(de)
|
2011-04-22 |
2021-10-13 |
The Regents of The University of California |
Adenoassoziierte virus-virionen mit veränderlichem kapsid und verwendungsverfahren dafür
|
CA2864100A1
(en)
*
|
2012-02-14 |
2013-08-22 |
The Regents Of The University Of California |
Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
CN104797593B
(zh)
|
2012-09-28 |
2020-05-08 |
北卡罗来纳-查佩尔山大学 |
靶向少突胶质细胞的aav载体
|
WO2014059173A2
(en)
|
2012-10-10 |
2014-04-17 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
EP3517612A1
(de)
|
2013-03-15 |
2019-07-31 |
The University of North Carolina At Chapel Hill |
Synthetische adenoassoziierte virusinvertierte endwiederholungssequenzen
|
US20160122727A1
(en)
|
2013-06-13 |
2016-05-05 |
Shire Human Genetic Therapies, Inc. |
Messenger rna based viral production
|
MX2016000345A
(es)
*
|
2013-07-12 |
2016-06-21 |
Philadelphia Children Hospital |
Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).
|
US20160354489A1
(en)
|
2013-09-26 |
2016-12-08 |
Universitat Autònome de Barcelona |
Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
|
CA2938669A1
(en)
|
2014-02-04 |
2015-08-13 |
Igenomx International Genomics Corporation |
Genome fractioning
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
DK3116900T3
(da)
|
2014-03-09 |
2020-09-28 |
Univ Pennsylvania |
Sammensætninger som kan anvendes til behandling af ornithintranscarbamylase (otc) defekt
|
EP3119797B1
(de)
|
2014-03-18 |
2020-12-23 |
University of Massachusetts |
Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
EP3194430A1
(de)
|
2014-09-16 |
2017-07-26 |
Universitat Autònoma De Barcelona |
Adeno-assoziierte virusvektoren zur gentheraüie von stoffwechselkrankheiten
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
EP3795580A1
(de)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
Hocheffiziente bibliotheksidentifizierte aav-vektoren
|
CA2964272A1
(en)
*
|
2014-10-21 |
2016-04-28 |
Guangping Gao |
Recombinant aav variants and uses thereof
|
SG10202007103TA
(en)
|
2014-11-05 |
2020-09-29 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
CA2975583A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
CN107532173A
(zh)
|
2014-11-21 |
2018-01-02 |
北卡罗来纳-查佩尔山大学 |
靶向中枢神经系统的aav载体
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
EP3242945B1
(de)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Einzelvektor-genkonstrukt mit insulin- und glucokinasegenen
|
JP6938377B2
(ja)
|
2015-01-14 |
2021-09-22 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
標的化遺伝子移入のための方法および組成物
|
CN107531774B
(zh)
|
2015-02-06 |
2021-12-14 |
北卡罗来纳大学查珀尔希尔分校 |
优化的人类凝血因子viii基因表达盒及其用途
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
US10968536B2
(en)
|
2015-02-25 |
2021-04-06 |
Jumpcode Genomics, Inc. |
Methods and compositions for sequencing
|
US10081659B2
(en)
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
US20190000943A1
(en)
*
|
2015-08-13 |
2019-01-03 |
Aavet Therapeutics, Llc |
Aav6 vectors for immunotherapy
|
EP3356390B1
(de)
|
2015-09-28 |
2021-01-20 |
The University of North Carolina at Chapel Hill |
Verfahren und zusammensetzungen für antikörperausweichende virusvektoren
|
US20190038659A1
(en)
|
2015-09-29 |
2019-02-07 |
The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating and preventing amyotrophic lateral sclerosis
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
EP3364996B1
(de)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Gegen die prostata gerichtete adeno-assoziierte virusserotypvektoren
|
WO2017077451A1
(en)
|
2015-11-05 |
2017-05-11 |
Bamboo Therapeutics, Inc. |
Modified friedreich ataxia genes and vectors for gene therapy
|
EP3384035A4
(de)
|
2015-12-02 |
2019-08-07 |
Voyager Therapeutics, Inc. |
Assays zum nachweis von aav-neutralisierenden antikörpern
|
CA3012409A1
(en)
*
|
2016-01-29 |
2017-08-03 |
Sirion Biotech Gmbh |
Aav-based conditional expression system
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
EP3411484B1
(de)
|
2016-02-05 |
2023-10-04 |
Emory University |
Injektion von einzelsträngigem oder selbstkomplementärem adeno-assoziiertem virus 9 in den liquor
|
US11702672B2
(en)
|
2016-02-08 |
2023-07-18 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
EP4094780A3
(de)
|
2016-02-12 |
2023-02-08 |
University of Massachusetts |
Anti-angiogene mirna-therapeutika zur hemmung der neovaskularisation der hornhaut
|
US11339427B2
(en)
|
2016-02-12 |
2022-05-24 |
Jumpcode Genomics, Inc. |
Method for target specific RNA transcription of DNA sequences
|
WO2017147123A1
(en)
|
2016-02-22 |
2017-08-31 |
The University Of North Carolina At Chapel Hill |
Aav-idua vector for treatment of mps i-associated blindness
|
MA43735A
(fr)
|
2016-03-07 |
2018-11-28 |
Univ Iowa Res Found |
Expression médiée par aav utilisant un promoteur et un activateur synthétiques
|
EP3440210A4
(de)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
Zusammensetzungen und verfahren zur selektiven hemmung der expression des grainyhead-like-proteins
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
WO2017190031A1
(en)
|
2016-04-28 |
2017-11-02 |
Indiana University Research And Technology Corporation |
Methods and compositions for resolving components of a virus preparation
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP4049683A1
(de)
|
2016-04-29 |
2022-08-31 |
Adverum Biotechnologies, Inc. |
Evasion von neutralisierenden antikörpern durch ein rekombinantes adeno-assoziiertes virus
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
CN109476707B
(zh)
|
2016-05-13 |
2022-12-02 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
CA3024448A1
(en)
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
KR102427379B1
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
EP3469080A4
(de)
|
2016-06-13 |
2020-01-22 |
The University of North Carolina at Chapel Hill |
Optimierte cln1-gene und expressionskassetten sowie deren verwendung
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
US11866480B2
(en)
|
2016-07-26 |
2024-01-09 |
The University Of North Carolina At Chapel Hill |
Vector-mediated immune tolerance in the eye
|
US11298041B2
(en)
|
2016-08-30 |
2022-04-12 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
US11578340B2
(en)
|
2016-10-13 |
2023-02-14 |
University Of Massachusetts |
AAV capsid designs
|
WO2018075798A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
EP3570895A1
(de)
|
2017-01-17 |
2019-11-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur expression eines bestimmten polynukleotids in den zapfen-fotorezeptoren
|
EP3575398A4
(de)
*
|
2017-01-30 |
2020-11-11 |
Nippon Medical School Foundation |
Mutant von capsid-protein des adeno-assoziierten virus (aav)
|
CA3054711A1
(en)
|
2017-03-15 |
2018-09-20 |
The University Of North Carolina At Chapel Hill |
Polyploid adeno-associated virus vectors and methods of making and using the same
|
EP3388520A1
(de)
|
2017-04-11 |
2018-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur reduzierung der expression von nkcc1 in einer darauf angewiesenen person
|
AU2018261003A1
(en)
|
2017-05-05 |
2019-11-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's Disease
|
EP3618839A4
(de)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als)
|
CA3059213A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
US20200207830A1
(en)
|
2017-07-27 |
2020-07-02 |
Novartis Ag |
Trem2 mutants resistant to sheddase cleavage
|
WO2019028306A2
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
|
KR20200042935A
(ko)
*
|
2017-08-25 |
2020-04-24 |
오비드 테라퓨틱스 인크. |
재조합 아데노-관련된 벡터들
|
WO2019060538A1
(en)
|
2017-09-20 |
2019-03-28 |
The Trustees Of Indiana University |
METHODS FOR LIPOPROTEIN RESOLUTION BY MASS SPECTROMETRY
|
FI3684423T3
(fi)
|
2017-09-20 |
2023-06-15 |
4D Molecular Therapeutics Inc |
Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
|
US11739330B2
(en)
|
2017-09-22 |
2023-08-29 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
CN111479924A
(zh)
|
2017-10-16 |
2020-07-31 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
EP3697908A1
(de)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Behandlung von amyotropher lateralsklerose (als)
|
EP3697448A1
(de)
|
2017-10-20 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur expression eines bestimmten polynukleotids in den zapfen-fotorezeptoren einer person mit subretinaler abgabe einer therapeutisch wirksamen menge eines rekombinanten aav9-vektors
|
BR112020008835A2
(pt)
|
2017-11-07 |
2020-10-20 |
The University Of North Carolina At Chapel Hill |
genes de aga otimizados e cassetes de expressão e seu uso
|
EP4219695A3
(de)
|
2017-11-27 |
2024-01-17 |
4D Molecular Therapeutics Inc. |
Kapside mit adeno-assoziierten virenvarianten und verwendung zur hemmung der angiogenese
|
WO2019140233A1
(en)
|
2018-01-12 |
2019-07-18 |
The Trustees Of Indiana University |
Electrostatic linear ion trap design for charge detection mass spectrometry
|
JP2021511020A
(ja)
*
|
2018-01-17 |
2021-05-06 |
アドリーナス セラピューティクス, インコーポレイテッド |
21−ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法
|
WO2019165058A1
(en)
|
2018-02-21 |
2019-08-29 |
Alcyone Lifesciences, Inc. |
Fluid delivery systems and methods
|
EP3774852A1
(de)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Antikörpermeidende virale vektoren
|
EP3774854A1
(de)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Antikörperausweichende virusvektoren
|
US20210371469A1
(en)
|
2018-04-03 |
2021-12-02 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019236143A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for calibrating or resetting a charge detector
|
EP3803951A1
(de)
|
2018-06-04 |
2021-04-14 |
The Trustees of Indiana University |
Ladungsdetektionsmassenspektrometrie mit echtzeitanalyse und signaloptimierung
|
CN112673452A
(zh)
|
2018-06-04 |
2021-04-16 |
印地安纳大学理事会 |
用于在静电线性离子阱中捕获离子的设备和方法
|
WO2019236139A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
|
CA3102587A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Ion trap array for high throughput charge detection mass spectrometry
|
EP3807404A1
(de)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Manipulierte 5'-unübersetzte regionen (5' utr) zur herstellung von aav
|
CA3107462A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
US20210316012A1
(en)
|
2018-08-10 |
2021-10-14 |
The University Of North Carolina At Chapel Hill |
Optimized cln7 genes and expression cassettes and their use
|
CA3110345A1
(en)
|
2018-08-27 |
2020-03-05 |
Alcyone Lifesciences, Inc. |
Fluid delivery systems and methods
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
EP3861113A1
(de)
|
2018-10-04 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Verfahren zur messung des titers und der potenz von viralen vektorpartikeln
|
JP2022512621A
(ja)
|
2018-10-05 |
2022-02-07 |
ボイジャー セラピューティクス インコーポレイテッド |
Aav産生タンパク質をコードする操作された核酸コンストラクト
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス/Sf9システムにおけるrAAVの大規模産生のための発現ベクター
|
CN113574632A
(zh)
|
2018-11-20 |
2021-10-29 |
印地安纳大学理事会 |
用于单粒子质谱分析的轨道阱
|
AU2019392058A1
(en)
|
2018-12-03 |
2021-05-27 |
The Trustees Of Indiana University |
Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
|
WO2020163379A1
(en)
|
2019-02-05 |
2020-08-13 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
US20220154157A1
(en)
|
2019-02-06 |
2022-05-19 |
Emendobio Inc. |
New engineered high fidelity cas9
|
JP2022520875A
(ja)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Biettiクリスタリン網膜症を治療するための組成物及び方法
|
EP3931334A1
(de)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Zusammensetzungen und verfahren zur behandlung von bietti-kristall-dystrophie
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
WO2020205889A1
(en)
*
|
2019-04-01 |
2020-10-08 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
JP2022530126A
(ja)
|
2019-04-23 |
2022-06-27 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
新規アデノ随伴ウイルス(aav)バリアント及び遺伝子治療のためのその使用
|
US11942317B2
(en)
|
2019-04-23 |
2024-03-26 |
The Trustees Of Indiana University |
Identification of sample subspecies based on particle mass and charge over a range of sample temperatures
|
WO2020219988A2
(en)
|
2019-04-26 |
2020-10-29 |
Sangamo Therapeutics, Inc. |
Engineering aav
|
WO2020232044A1
(en)
*
|
2019-05-14 |
2020-11-19 |
Biomarin Pharmaceutical Inc. |
Methods of redosing gene therapy vectors
|
SG11202112917PA
(en)
|
2019-05-24 |
2021-12-30 |
Regeneron Pharma |
Modified viral particles and uses thereof
|
EP3990030A1
(de)
|
2019-06-27 |
2022-05-04 |
Pfizer Inc. |
Verfahren zur behandlung von duchenne-muskeldystrophie mittels aav-mini-dystrophin-gentherapie
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
GB201913974D0
(en)
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
IL292297A
(en)
|
2019-10-17 |
2022-06-01 |
Stridebio Inc |
Adeno-associated viral vectors for the treatment of Niemann-Pick type c disease
|
JP2023515820A
(ja)
|
2020-02-28 |
2023-04-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
メープルシロップ尿症の遺伝子治療
|
WO2021188960A1
(en)
|
2020-03-20 |
2021-09-23 |
University Of Florida Research Foundation, Inc. |
Gene therapy for cockayne syndrome
|
AU2021254272A1
(en)
|
2020-04-10 |
2022-10-27 |
Sola Biosciences Llc |
Compositions and methods for the treatment of protein aggregation disorders
|
BR112022021604A2
(pt)
|
2020-04-28 |
2022-12-06 |
Sola Biosciences Llc |
Composições e métodos para tratamento de proteinopatias associadas à tdp-43
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
EP4161953A1
(de)
|
2020-06-05 |
2023-04-12 |
SOLA Biosciences LLC |
Zusammensetzungen und verfahren zur behandlung von synukleinopathien
|
EP4240861A1
(de)
|
2020-11-03 |
2023-09-13 |
Pfizer Inc. |
Verfahren zur reinigung von aav-vektoren durch anionenaustauschchromatografie
|
US20240052322A1
(en)
|
2020-12-15 |
2024-02-15 |
Pfizer Inc. |
HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
|
CA3205924A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
TW202242124A
(zh)
|
2021-01-14 |
2022-11-01 |
美商史崔德生物公司 |
靶向t細胞之aav載體
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
CN117377500A
(zh)
|
2021-04-26 |
2024-01-09 |
阿雷克森国际制药有限公司 |
具有改善的组织向性的腺相关病毒载体衣壳
|
EP4349852A1
(de)
|
2021-05-28 |
2024-04-10 |
Shanghai Regenelead Therapies Co., Ltd. |
Rekombinantes adeno-assoziiertes virus mit veränderlichem kapsid und anwendung davon
|
US20220396798A1
(en)
*
|
2021-06-12 |
2022-12-15 |
Shi-Lung Lin |
Novel mrna composition and production method for use in anti-viral and anti-cancer vaccines
|
WO2022269466A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
AR126407A1
(es)
|
2021-07-08 |
2023-10-11 |
Tenaya Therapeutics Inc |
Casetes de expresión optimizada para genoterapia
|
AU2022327583A1
(en)
|
2021-08-11 |
2024-02-22 |
King's College London |
Compositions and methods for improved treatment of disorders affecting the central nervous system
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
US20230241118A1
(en)
|
2021-10-20 |
2023-08-03 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
CA3233698A1
(en)
|
2021-11-04 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to skeletal muscle
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
TW202342759A
(zh)
|
2022-02-04 |
2023-11-01 |
美商史崔德生物公司 |
重組腺相關病毒載體及其使用方法
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
WO2024026494A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to transferrin receptor 1
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|